Illumina Slapped with a Staggering $400 Million Fine in Landmark Case
In a stunning blow to the genomics industry, Illumina, the leading provider of DNA sequencing technology, has been hit with a record-breaking fine of $400 million by regulatory authorities. The fine comes as a result of alleged anti-competitive practices and breaches of fair trade regulations that have shaken the biotechnology community and left investors and stakeholders in a state of shock.